vs
Grocery Outlet Holding Corp.（GO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Grocery Outlet Holding Corp.的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs -18.5%，领先31.2%），Grocery Outlet Holding Corp.同比增速更快（10.7% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 8.3%）
Grocery Outlet Holding Corp.是美国知名的折扣清仓零售企业，旗下所有门店均为超市，主打销售品牌厂商及自有品牌供应商的库存积压与清仓商品，价格优惠。目前该公司的门店已分布在美国加利福尼亚、俄勒冈、华盛顿、爱达荷等十余州。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GO vs RVTY — 直观对比
营收规模更大
GO
是对方的1.6倍
$772.1M
营收增速更快
GO
高出4.8%
5.9%
净利率更高
RVTY
高出31.2%
-18.5%
两年增速更快
RVTY
近两年复合增速
8.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $-224.9M | $98.4M |
| 毛利率 | 29.7% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -18.5% | 12.7% |
| 营收同比 | 10.7% | 5.9% |
| 净利润同比 | -669.9% | 3.9% |
| 每股收益（稀释后） | $-2.22 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GORVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | — | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润GORVTY
| Q1 26 | $-224.9M | — | ||
| Q4 25 | — | $98.4M | ||
| Q3 25 | $11.6M | $46.7M | ||
| Q2 25 | $5.0M | $53.9M | ||
| Q1 25 | $-23.3M | $42.2M | ||
| Q4 24 | $2.3M | $94.6M | ||
| Q3 24 | $24.2M | $94.4M | ||
| Q2 24 | $14.0M | $55.4M |
毛利率GORVTY
| Q1 26 | 29.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 30.4% | 53.6% | ||
| Q2 25 | 30.6% | 54.5% | ||
| Q1 25 | 30.4% | 56.5% | ||
| Q4 24 | 29.5% | — | ||
| Q3 24 | 31.1% | 56.3% | ||
| Q2 24 | 30.9% | 55.7% |
营业利润率GORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | 2.0% | 11.7% | ||
| Q2 25 | 1.1% | 12.6% | ||
| Q1 25 | -2.0% | 10.9% | ||
| Q4 24 | 1.0% | 16.3% | ||
| Q3 24 | 3.6% | 14.3% | ||
| Q2 24 | 2.3% | 12.4% |
净利率GORVTY
| Q1 26 | -18.5% | — | ||
| Q4 25 | — | 12.7% | ||
| Q3 25 | 1.0% | 6.7% | ||
| Q2 25 | 0.4% | 7.5% | ||
| Q1 25 | -2.1% | 6.4% | ||
| Q4 24 | 0.2% | 13.0% | ||
| Q3 24 | 2.2% | 13.8% | ||
| Q2 24 | 1.2% | 8.0% |
每股收益（稀释后）GORVTY
| Q1 26 | $-2.22 | — | ||
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.12 | $0.40 | ||
| Q2 25 | $0.05 | $0.46 | ||
| Q1 25 | $-0.24 | $0.35 | ||
| Q4 24 | $0.03 | $0.77 | ||
| Q3 24 | $0.24 | $0.77 | ||
| Q2 24 | $0.14 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.6M | $919.9M |
| 总债务越低越好 | $15.0M | — |
| 股东权益账面价值 | $983.7M | $7.3B |
| 总资产 | $3.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资GORVTY
| Q1 26 | $69.6M | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | $52.1M | $931.4M | ||
| Q2 25 | $55.2M | $991.8M | ||
| Q1 25 | $50.9M | $1.1B | ||
| Q4 24 | $62.8M | $1.2B | ||
| Q3 24 | $68.7M | $1.2B | ||
| Q2 24 | $67.1M | $2.0B |
总债务GORVTY
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $500.3M | — | ||
| Q2 25 | $473.9M | — | ||
| Q1 25 | $475.7M | — | ||
| Q4 24 | $477.5M | — | ||
| Q3 24 | $429.3M | — | ||
| Q2 24 | $379.2M | — |
股东权益GORVTY
| Q1 26 | $983.7M | — | ||
| Q4 25 | — | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B |
总资产GORVTY
| Q1 26 | $3.1B | — | ||
| Q4 25 | — | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.3B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.2B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B | ||
| Q2 24 | $3.1B | $13.4B |
负债/权益比GORVTY
| Q1 26 | 0.02× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $222.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GORVTY
| Q1 26 | $222.1M | — | ||
| Q4 25 | — | $182.0M | ||
| Q3 25 | $17.3M | $138.5M | ||
| Q2 25 | $73.6M | $134.3M | ||
| Q1 25 | $58.9M | $128.2M | ||
| Q4 24 | $39.5M | $174.2M | ||
| Q3 24 | $23.0M | $147.9M | ||
| Q2 24 | $41.6M | $158.6M |
自由现金流GORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | $-21.6M | $120.0M | ||
| Q2 25 | $14.4M | $115.5M | ||
| Q1 25 | $-1.5M | $112.2M | ||
| Q4 24 | $-19.6M | $149.8M | ||
| Q3 24 | $-19.3M | $125.6M | ||
| Q2 24 | $2.7M | $136.6M |
自由现金流率GORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | -1.8% | 17.2% | ||
| Q2 25 | 1.2% | 16.0% | ||
| Q1 25 | -0.1% | 16.9% | ||
| Q4 24 | -1.8% | 20.5% | ||
| Q3 24 | -1.7% | 18.4% | ||
| Q2 24 | 0.2% | 19.7% |
资本支出强度GORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 5.0% | 2.6% | ||
| Q1 25 | 5.4% | 2.4% | ||
| Q4 24 | 5.4% | 3.4% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 3.4% | 3.2% |
现金转化率GORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.49× | 2.97× | ||
| Q2 25 | 14.84× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 17.09× | 1.84× | ||
| Q3 24 | 0.95× | 1.57× | ||
| Q2 24 | 2.97× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GO
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
